Literature DB >> 11571511

High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.

S Kumar1, A Dispenzieri, M Q Lacy, M R Litzow, M A Gertz.   

Abstract

Peripheral blood stem cell transplants have been associated with better response rates than conventional chemotherapy in patients with primary systemic amyloidosis. A higher incidence of gastrointestinal (GI) tract bleeding has been observed among amyloidosis patients undergoing peripheral stem cell transplantation. We retrospectively reviewed the medical records of such patients to identify those who had GI tract bleeding in the post-transplant period. Forty-five patients were studied. Nine patients had GI tract bleeding in the post-transplant period. The median post-transplant duration to onset of bleeding was 9.5 days (range 1 to 48 days). Three patients had lower GI tract bleeding, two had upper GI tract bleeding, and four had both. Diffuse esophagitis and gastritis were the most common findings on endoscopy. There were no correlations among the age, platelet nadir, or CD34 count of the graft and the risk of bleeding. Women were more likely to have GI tract bleeding (P = 0.015), as were patients with slow platelet engraftment (P = 0.02). Patients with multiorgan involvement and those on hemodialysis appeared to be at a higher risk of GI tract bleeding. The mean post-transplant hospital stay for those with GI tract bleeding was 37 days compared with 14.5 days for those who did not have GI tract bleeding (P = 0.0047).

Entities:  

Mesh:

Year:  2001        PMID: 11571511     DOI: 10.1038/sj.bmt.1703155

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

Review 1.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

2.  Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models.

Authors:  Xueyan Sun; Yan Su; Xiao Liu; Yuanyuan Zhang; Yun He; Wei Han; Qi Chen; Huan Chen; Yu Wang; Yifei Cheng; Fengqi Liu; Fengrong Wang; Yao Chen; Gaochao Zhang; Xiaodong Mo; Haixia Fu; Yuhong Chen; Jingzhi Wang; Xiaolu Zhu; Lanping Xu; Kaiyan Liu; Xiaojun Huang; Xiaohui Zhang
Journal:  Bone Marrow Transplant       Date:  2021-01-07       Impact factor: 5.483

Review 3.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

4.  Current treatment in cardiac amyloidosis.

Authors:  Ivana Kholová; Josef Kautzner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

Review 5.  Successful perioperative management of factor X deficiency associated with primary amyloidosis.

Authors:  Kazuaki Takabe; Peter R Holman; Kenneth D Herbst; Catherine A Glass; Michael Bouvet
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

6.  Gastrointestinal Amyloidosis: Approach to Treatment.

Authors:  Peter D. Poullos; Neil Stollman
Journal:  Curr Treat Options Gastroenterol       Date:  2003-02

7.  Novel Endoscopic Finding Associated With Gastrointestinal Hemorrhage in a Post-Stem Cell Transplant Patient With Light Chain Amyloidosis.

Authors:  Seema Gandhi; Shifali Arora; Michael Brown; Shiram Jakate
Journal:  ACG Case Rep J       Date:  2015-04-10

Review 8.  Thromboembolism and bleeding in systemic amyloidosis: a review.

Authors:  Martin Nicol; Virginie Siguret; Giuseppe Vergaro; Alberto Aimo; Michele Emdin; Jean Guillaume Dillinger; Mathilde Baudet; Alain Cohen-Solal; Camille Villesuzanne; Stephanie Harel; Bruno Royer; Bertrand Arnulf; Damien Logeart
Journal:  ESC Heart Fail       Date:  2021-11-16

Review 9.  Recent advances in understanding and treating immunoglobulin light chain amyloidosis.

Authors:  Talha Badar; Anita D'Souza; Parameswaran Hari
Journal:  F1000Res       Date:  2018-08-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.